Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flt-3-ligand + granulocyte-colony stimulating factor
- Development stage
- Unknown
- Lead developer
- Albert Einstein College of Medicine
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of flt-3-ligand (FL) and granulocyte colony-stimulating factor (G-CSF), both recombinant protein cytokines. This combination is used experimentally to synergistically mobilize hematopoietic stem cells (HSCs) and progenitor cells from the bone marrow into the peripheral blood. FL primarily stimulates proliferation of early hematopoietic progenitors by activating the Fms-like tyrosine kinase 3 receptor (FLT3), while G-CSF promotes proliferation and differentiation of neutrophil precursors via the granulocyte colony-stimulating factor receptor. When administered together, they significantly increase the number of circulating HSCs and facilitating cells compared to either agent alone, enhancing engraftment potential for transplantation settings[1][2][4]. The combination has been studied in preclinical models for its ability to improve peripheral blood stem cell mobilization and long-term multilineage hematopoietic reconstitution.
- Other names
- flt3 ligand + G-CSFFL + G-CSFFlt3L + G-CSF
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on flt-3-ligand + granulocyte-colony stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flt-3-ligand + granulocyte-colony stimulating factor.